This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Speirs, R. J.
Right arrow Articles by Cynamon, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Speirs, R. J.
Right arrow Articles by Cynamon, M. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 06 1995, 1269-1271, Vol 39, No. 6
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide

RJ Speirs, JT Welch and MH Cynamon
Veterans Affairs Medical Center, Syracuse, New York 13210, USA.

The mechanism of action of pyrazinamide (PZA) is not known. One hypothesis is that PZA functions as a prodrug of pyrazinoic acid. Susceptibility to PZA correlates with amidase activity of the Mycobacterium tuberculosis isolate in question. PZA-resistant isolates retain susceptibility in vitro to pyrazinoic acid and n-propyl pyrazinoate. Esters of pyrazinoic acid appear to circumvent the requirement for activation by mycobacterial amidase. The MICs of n- propyl pyrazinoate for M. tuberculosis isolates are lower than those of pyrazinoic acid. Further studies to assess the effects of modifications of the alcohol and pyrazine moieties of pyrazinoate esters on in vitro and in vivo antituberculosis activity are under way. This may lead to a candidate compound with enhanced activity against both PZA-susceptible and PZA-resistant M. tuberculosis isolates suitable for clinical development.


This article has been cited by other articles:

  • Mendez, S., Traslavina, R., Hinchman, M., Huang, L., Green, P., Cynamon, M. H., Welch, J. T. (2009). The Antituberculosis Drug Pyrazinamide Affects the Course of Cutaneous Leishmaniasis In Vivo and Increases Activation of Macrophages and Dendritic Cells. Antimicrob. Agents Chemother. 53: 5114-5121 [Abstract] [Full Text]  
  • Zimhony, O., Vilcheze, C., Arai, M., Welch, J. T., Jacobs, W. R. Jr. (2007). Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli. Antimicrob. Agents Chemother. 51: 752-754 [Abstract] [Full Text]  
  • Barco, P., Cardoso, R. F., Hirata, R. D. C., Leite, C. Q. F., Pandolfi, J. R., Sato, D. N., Shikama, M. L., de Melo, F. F., Mamizuka, E. M., Campanerut, P. A. Z., Hirata, M. H. (2006). pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother 58: 930-935 [Abstract] [Full Text]  
  • Mohamed, A. M., Bastola, D. R., Morlock, G. P., Cooksey, R. C., Hinrichs, S. H. (2004). Temperature-Mediated Heteroduplex Analysis for Detection of pncA Mutations Associated with Pyrazinamide Resistance and Differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by Denaturing High- Performance Liquid Chromatography. J. Clin. Microbiol. 42: 1016-1023 [Abstract] [Full Text]  
  • Madison, B., Gross, W., George, I., Sloutsky, A., Washabaugh, G., Robinson-Dunn, B., Lipman, H., Metchock, B., Mazurek, G., Ridderhof, J. (2002). Multicenter Evaluation of a Nonweekend Reading Schedule for Radiometric Pyrazinamide Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 40: 3753-3756 [Abstract] [Full Text]  
  • ZHANG, Y., PERMAR, S., SUN, Z. (2002). Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51: 42-49 [Abstract] [Full Text]  
  • Marttila, H. J., Marjamäki, M., Vyshnevskaya, E., Vyshnevskiy, B. I., Otten, T. F., Vasilyef, A. V., Viljanen, M. K. (1999). pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates from Northwestern Russia. Antimicrob. Agents Chemother. 43: 1764-1766 [Abstract] [Full Text]  
  • Sun, Z., Zhang, Y. (1999). Reduced Pyrazinamidase Activity and the Natural Resistance of Mycobacterium kansasii to the Antituberculosis Drug Pyrazinamide. Antimicrob. Agents Chemother. 43: 537-542 [Abstract] [Full Text]  
  • Cynamon, M. H., Speirs, R. J., Welch, J. T. (1998). In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide. Antimicrob. Agents Chemother. 42: 462-463 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»